Osmohale (Mannitol)

Mannitol, the active ingredient in Osmohale, is an excipient presented as a powder for inhalation use. It creates an osmotic gradient that draws water into the airway lumen, facilitating mucociliary clearance in patients requiring inhalation therapy.

GNH USA supplies Osmohale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mannitol is used as an excipient in inhalation formulations to support airway clearance.

Bronchial obstruction: enhances mucociliary clearance in obstructive airway diseases. Cystic fibrosis: facilitates removal of thick mucus from the lungs. Chronic obstructive pulmonary disease (COPD): aids airway hydration and mucus clearance.

Mannitol may cause a range of respiratory and systemic reactions.

Common Side Effects: - Cough: transient irritation leading to coughing. - Throat irritation: mild discomfort in the throat. - Bronchospasm: temporary narrowing of the airways. - Wheezing: audible breath sounds during exhalation. - Headache: mild to moderate head pain. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Severe bronchospasm: pronounced airway constriction requiring medical attention. - Anaphylaxis: rare systemic allergic reaction. - Pulmonary edema: accumulation of fluid in the lungs. - Hemoptysis: coughing up blood. - Severe allergic reaction: rash, swelling, or difficulty breathing.

When using inhaled mannitol, consider the following precautions.

Assess airway reactivity: perform bronchial provocation testing before initiating therapy. Monitor lung function: check spirometry after the first doses. Avoid in uncontrolled asthma: increased risk of bronchospasm. Use with caution in hypersensitivity: discontinue if allergic signs appear. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep in original container, protect from moisture and heat.

Mannitol may interact with other agents affecting the respiratory system.

Major Interactions (Avoid): - Concurrent inhaled osmotic agents: may exacerbate airway irritation. - Beta‑agonists: may mask bronchospasm symptoms, delaying recognition.

Moderate Interactions (Monitor Closely): - Anticholinergics: could alter airway secretions. - Systemic diuretics: potential additive osmotic effects. - Other excipients with irritant potential: monitor for increased cough or throat discomfort.